Pacific Biosciences of California, Inc.
PACB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $38,441 | $39,766 | $37,153 | $39,224 |
| % Growth | -3.3% | 7% | -5.3% | – |
| Cost of Goods Sold | $22,540 | $25,082 | $38,524 | $29,166 |
| Gross Profit | $15,901 | $14,684 | -$1,371 | $10,058 |
| % Margin | 41.4% | 36.9% | -3.7% | 25.6% |
| R&D Expenses | $22,846 | $22,529 | $29,053 | $27,466 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $31,099 | $36,175 | $40,168 | $41,148 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $833 | $358,342 | $94,472 |
| Operating Expenses | $53,945 | $59,537 | $427,563 | $163,086 |
| Operating Income | -$38,044 | -$44,853 | -$428,934 | -$153,028 |
| % Margin | -99% | -112.8% | -1,154.5% | -390.1% |
| Other Income/Exp. Net | $427 | $2,958 | $2,557 | $155,715 |
| Pre-Tax Income | -$37,617 | -$41,895 | -$426,377 | $2,687 |
| Tax Expense | $383 | $35 | -$302 | $316 |
| Net Income | -$38,000 | -$41,930 | -$426,075 | $2,371 |
| % Margin | -98.9% | -105.4% | -1,146.8% | 6% |
| EPS | -0.13 | -0.14 | -1.44 | 0.008 |
| % Growth | 7.1% | 90.3% | -17,242.9% | – |
| EPS Diluted | -0.13 | -0.14 | -1.44 | 0.008 |
| Weighted Avg Shares Out | 300,844 | 300,162 | 296,858 | 282,999 |
| Weighted Avg Shares Out Dil | 300,844 | 300,162 | 296,858 | 306,892 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1,739 | $1,738 | $1,737 | $2,757 |
| Depreciation & Amortization | $3,481 | $4,582 | $372,779 | $10,949 |
| EBITDA | -$32,397 | -$35,575 | -$51,861 | $16,393 |
| % Margin | -84.3% | -89.5% | -139.6% | 41.8% |